Quantcast

Latest Proteasome inhibitor Stories

2009-12-07 14:17:48

Carfilzomib induces a response in 45 percent of patients and reduces neuropathy The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meeting of the American Society of Hematology. The updated data from the 17-site study focuses on patients with relapsed or resistant multiple myeloma who have received one to...

2009-12-07 07:00:00

NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib. Results demonstrated promising overall response rates when carfilzomib was administered as a single agent in patients with relapsed and/or refractory multiple myeloma. These data were presented at the 51st annual meeting of the American Society of Hematology (ASH) in...

2009-11-16 08:29:00

EMERYVILLE, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. "With the close of this strategic transaction, Onyx reaches an important milestone in its evolution as a leading...

2009-11-10 15:00:00

EMERYVILLE, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple...

2009-10-17 08:00:00

SOUTH SAN FRANCISCO, Oct. 17 /PRNewswire/ -- Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors, and is currently enrolling patients in multiple oncology clinical trials, including a Phase 2 study in patients with relapsed and refractory multiple...

2009-10-12 07:00:00

EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast, led by external medical experts, to discuss the multiple myeloma market and provide an overview of the carfilzomib clinical program. The webcast will take place today at 11:00 a.m. ET, and can be accessed at http://www.onyx-pharm.com/view.cfm/32/Event-Calendar. The event follows the announcement of Onyx's intention to acquire Proteolix, Inc., a...

2009-10-12 06:00:00

SOUTH SAN FRANCISCO, Calif., Oct. 12 /PRNewswire/ -- Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX). Proteolix is a privately-held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix's lead compound, carfilzomib, is a proteasome inhibitor currently in multiple clinical...

2009-10-12 05:58:00

EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has signed a definitive agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix's lead compound, carfilzomib, is a proteasome inhibitor currently in multiple clinical trials, including...

2009-09-16 14:09:22

Compounds that kill dormant pathogen while sparing human cells could lead to new drugs Attempts to eradicate tuberculosis (TB) are stymied by the fact that the disease-causing bacteria have a sophisticated mechanism for surviving dormant in infected cells. Now, a team of scientists including researchers from the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, Stony Brook University (SBU), Weill Cornell Medical College, and The Rockefeller University has identified compounds...

2009-06-08 07:30:00

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Relapsed Multiple Myeloma...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related